WeightWatchers’ Scott Honken on rethinking success in the age of GLP-1s

As excitement builds around GLP-1s and their expanding list of potential indications, the conversation is shifting from hype to hard questions. From adherence to access, it’s clear there’s still work to be done to unlock the full potential of this drug class.

At HLTH Europe, Deep Dive editor Eloise McLennan sat down with Scott Honken, chief commercial officer at WeightWatchers, to explore the company’s pivot into the GLP-1 space – and the realities behind the buzz.

Drawing on WeightWatchers’ longstanding role in the weight management landscape, Honken shares insights into persistent challenges around ROI, coverage, and patient adherence. He also makes the case for moving beyond BMI as the primary measure of success — and explains why GLP-1s, while promising, are far from a silver bullet.

Check out the full interview below, and listen to our full breakdown of trends and innovation from HLTH Europe 2025 here.